PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24985179-6	2014	RESULTS: tDCs induced by tacrolimus exhibit a typical tolerogenic phenotype, whose level of costimulatory molecules CD80, CD83, CD86 and HLA-DR is (2.95 +- 1.32)%, (2.33 +- 1.60)%, (90.02 +- 7.42)% and (91.80 +- 6.18)%, respectively.	Tacrolimus	25-35	CD86 molecule	Homo sapiens	128-132	
18547634-6	2008	RESULTS: Tacrolimus and TGF-beta1 act synergistically on the generation of LCs and the expression of CD40, CD80, CD86, CD83, and MHC II; stabilize TGF-beta receptor II expression; and decrease the stimulatory capacity of LCs toward T cells.	Tacrolimus	9-19	CD86 molecule	Homo sapiens	113-117	
15241357-8	2004	RESULTS: Tacrolimus and steroid ointment induced a selective depletion of IDECs from the epidermis and reduced the expression of the costimulatory molecules CD80 and CD86.	Tacrolimus	9-19	CD86 molecule	Homo sapiens	166-170	
12091117-10	2002	We found a decrease in CD1a median fluorescence intensity (MFI) and an increase in percentage of CD86-positive cells with lengthy exposure (6 days) to FK506 at 5000 ng/mL.	Tacrolimus	151-156	CD86 molecule	Homo sapiens	97-101	
12091117-11	2002	In the sequential study, 5000 ng/mL FK506 before LPS addition resulted in a significant decrease in CD1a MFI and in the percentage of cells co-expressing CD83 and CD86.	Tacrolimus	36-41	CD86 molecule	Homo sapiens	163-167